BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehrpouri M. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Yang K, Zhang H. Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia? Cancers 2022;14:5655. [DOI: 10.3390/cancers14225655] [Reference Citation Analysis]
2 Luciano M, Krenn PW, Horejs-hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol 2022;13:1000996. [DOI: 10.3389/fimmu.2022.1000996] [Reference Citation Analysis]
3 Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D’huyvetter M. Radiotheranostic Agents in Hematological Malignancies. Front Immunol 2022;13:911080. [DOI: 10.3389/fimmu.2022.911080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zaczyńska E, Kaczmarek K, Zabrocki J, Artym J, Zimecki M. Antiviral Activity of a Cyclic Pro-Pro-β3-HoPhe-Phe Tetrapeptide against HSV-1 and HAdV-5. Molecules 2022;27:3552. [PMID: 35684487 DOI: 10.3390/molecules27113552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]